GlycoGenesys initiates trial at Dana-Farber

GlycoGenesys Inc. recently launched a Phase I-II clinical trial of its cancer drug candidate GCS-100LE in multiple myeloma patients.

The primary objective of the Phase I-II dose escalation study is to evaluate the safety of GCS-100LE when given to patients with relapsed or refractory multiple myeloma and to identify the recommended dose for future studies.